Fanny Escudie

Mrs. Fanny Escudie

Drugs for Neglected Diseases Initiative, Geneva, Genève, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RARana Abdelnabi
Rana Abdelnabi
CFCaroline Shi-Yan Foo
Caroline Shi-Yan Foo
DJDIRK JOCHMANS
DIRK JOCHMANS
LVLaura Vangeel
Laura Vangeel
SJSteven De Jonghe
Steven De Jonghe
JNJohan Hendrik Neyts
Johan Hendrik Neyts
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.

21 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
JMJames M. Murithi
James M. Murithi
CPCécile Pascal
Cécile Pascal
JBJade Bath
Jade Bath
XBXavier Boulenc
Xavier Boulenc
NGNina F. Gnädig
Nina F. Gnädig
DLDidier Leroy
Didier Leroy
We report an acylguanidine preclinical candidate with pharmacological features compatible with single low-dose malaria cure.

24 January 2024 in Antiviral Research
Verified
Journal Article
Open access
HBHawa Sophia Bouzidi
Hawa Sophia Bouzidi
JDJean-Sélim Driouich
Jean-Sélim Driouich
Raphaëlle KlittingRaphaëlle Klitting
Raphaëlle Klitting
OBOrnéllie Bernadin
Ornéllie Bernadin
GPGéraldine Piorkowski
Géraldine Piorkowski
Franck TouretFranck Touret
Franck Touret
Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has shown the best results in clinical trials and the greatest robustness against variants. A second SARS-CoV-2 protease inhibitor, ensitrelvir (Xocova®), has been developed. Ensitrelvir, currently in Phase 3, was approved in Japan under the emergency regulatory approval procedure in November 2022, and is available since March 31, 2023. One of the limitations for the use of antiviral monotherapies is the emergence of resistance mutations. Here, we experimentally generated mutants resistant to nirmatrelvir and ensitrelvir in vitro following repeating passages of SARS-CoV-2 in the presence of both antivirals. For both molecules, we demonstrated a loss of sensitivity for resistance mutants in vitro. Using a Syrian golden hamster infection model, we showed that the ensitrelvir M49L mutation, in the multi-passage strain, confers a high level of in vivo resistance. Finally, we identified a recent increase in the prevalence of M49L-carrying sequences, which appears to be associated with multiple repeated emergence events in Japan and may be related to the use of Xocova® in the country since November 2022. These results highlight the strategic importance of genetic monitoring of circulating SARS-CoV-2 strains to ensure that treatments administered retain their full effectiveness.

11 July 2022 in EBioMedicine
Verified
Journal Article
Open access
JDJean-Sélim Driouich
Jean-Sélim Driouich
MCMaxime COCHIN
Maxime COCHIN
Franck TouretFranck Touret
Franck Touret
PPPaul-Rémi Petit
Paul-Rémi Petit
MGMagali Gilles
Magali Gilles
ANAntoine Nougairède
Antoine Nougairède
To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started, including those involving an oral treatment by nitazoxanide, despite no or limited pre-clinical evidence of antiviral efficacy. In this work, we present a complete pre-clinical evaluation of the antiviral activity of nitazoxanide against SARS-CoV-2. First, we confirmed the in vitro efficacy of nitazoxanide and tizoxanide (its active metabolite) against SARS-CoV-2. Then, we demonstrated nitazoxanide activity in a reconstructed bronchial human airway epithelium model. In a SARS-CoV-2 virus challenge model in hamsters, oral and intranasal treatment with nitazoxanide failed to impair viral replication in commonly affected organs. We hypothesized that this could be due to insufficient diffusion of the drug into organs of interest. Indeed, our pharmacokinetic study confirmed that concentrations of tizoxanide in organs of interest were always below the in vitro EC50. These preclinical results suggest, if directly applicable to humans, that the standard formulation and dosage of nitazoxanide is not effective in providing antiviral therapy for Covid-19. This work was supported by the Fondation de France “call FLASH COVID-19”, project TAMAC, by “Institut national de la santé et de la recherche médicale” through the REACTing (REsearch and ACTion targeting emerging infectious diseases), by REACTING/ANRS MIE under the agreement No. 21180 (‘Activité des molécules antivirales dans le modèle hamster’), by European Virus Archive Global (EVA 213 GLOBAL) funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 871029 and DNDi under support by the Wellcome Trust Grant ref: 222489/Z/21/Z through the COVID-19 Therapeutics Accelerator”.

12 August 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
FAFrauke Assmus
Frauke Assmus
JDJean-Sélim Driouich
Jean-Sélim Driouich
RARana Abdelnabi
Rana Abdelnabi
LVLaura Vangeel
Laura Vangeel
Franck TouretFranck Touret
Franck Touret
ECEric Chatelain
Eric Chatelain
In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.

20 March 2022 in Analytical Biochemistry
Verified
Journal Article
Open access
PFPatrick Valere Tsouh Fokou
Patrick Valere Tsouh Fokou
MTMariscal Brice TCHATAT TALI
Mariscal Brice TCHATAT TALI
DDDarline Dize
Darline Dize
CMCedric Derick Jiatsa Mbouna
Cedric Derick Jiatsa Mbouna
CNCyrille Armel Njampa Ngansop
Cyrille Armel Njampa Ngansop
FBFabrice Fekam Boyom
Fabrice Fekam Boyom
Antimalarial drug discovery has been facilitated by the development of various in vitro drug susceptibility testing methods suitable for medium-throughput or high-throughput campaigns. Among many, the Plasmodium falciparum lactate dehydrogenase (PfLDH) assay has acceptable demand on equipment, labour, technical skills and affordability and offers a good opportunity for scientists in low- and middle-income countries to participate in the global effort of discovering future antimalarial drugs. Hence, to enable our search for novel antimalarial drugs, we implemented and examined assay conditions and validated the PfLDH-based method in our laboratory using a reference set of standard antimalarial drugs with known activity against Plasmodium falciparum strains. The PfLDH assay revealed acceptable linearity profiles of R2 = 0.97 and 0.92 for Pf3D7 and PfDd2, respectively, achieved at 2% parasitaemia and 1% haematocrit. The detection and quantitation limits (DL and QL) of the PfLDH-based assay were 0.09% and 0.4% parasitemia, respectively. The assay showed an acceptable average Z-factor between 0.76 and 0.79 and was considerably robust. The average interassay reproducibility via percent coefficient of variation (%CV) was 5.47 between independent experiments. Overall, the PfLDH-based method produced a reliable and reproducible drug screening profile for in vitro assays in our setting. There were no significant interassay variability or hazards of other screening assays.